Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression




Michal Schnaider Beeri, PhD, and Joshua Sonnen, MD


Despite great scientific efforts to find treatments for Alzheimer disease (AD), only 5 medications are marketed, with limited beneficial effects on symptoms, on a limited proportion of patients, without modification of the disease course. The prevalence of AD doubles every 5 years, reaching the alarming rate of 50% in those aged 85 years and older. In the context of the demographic trends of modern society, where the elderly are the fastest growing segment of the population, identification of new therapeutic targets that may prevent, delay, or cure AD is critically needed.


January 16, 2016

View study

Share this study